Inflammatory Bowel Diseases Crohn’S Disease

Pediatric patients with hidradenitis suppurativa are more than four times more likely to have Crohn’s disease compared with those without hidradenitis suppurativa, according to a study.

Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

The first reported incident of emphysematous cystitis in a patient with severe Crohn’s disease, without UTI or fistulizing disease, may signal “poor prognosis” for these patients, according to a case report published in BMC Gastroenterology.

NAPLES, Florida — Asad Ur Rahman, MD, a gastroenterologist at Cleveland Clinic Florida, spoke with Healio about highlights from three presentations he attended at the 2022 ACG/FGS Spring Symposium.

Patients with ulcerative colitis treated with Rinvoq 45 mg once daily experienced significant improvement in symptoms “as early as day 1,” according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

Higher ustekinumab trough concentration levels correlated with increased rates of endoscopic remission among patients with Crohn’s disease, according to research published in BMC Gastroenterology.

Adalimumab biosimilar BI 695501 demonstrated similar safety and efficacy compared with adalimumab reference product among patients with Crohn’s disease, according to research published in the Lancet Gastroenterology and Hepatology.